10-Q: TNF Pharma Q2: Losses Narrow, Capital Concerns Persist

TNF Pharmaceuticals, Inc. reported a significant reduction in net loss for the first half of 2025, driven by non-cash gains, but faces ongoing liquidity challenges and Nasdaq listing compliance issues.

Summary

• Net loss for the six months ended June 30, 2025, significantly narrowed to $2.92 million from $19.37 million in the prior year period.
• Net loss attributable to common stockholders improved to $4.71 million from $21.34 million year-over-year.
• Basic and diluted loss per common share improved to $(0.45) from $(9.58).
• Cash on hand increased to $207,553 as of June 30, 2025, from $173,154 at December 31, 2024.
• Marketable securities decreased significantly to $3.61 million from $8.35 million.
• Working capital turned negative, standing at $(397,585) as of June 30, 2025, compared to $2.71 million at December 31, 2024.
• Cash used in operating activities increased to $4.71 million for the six months ended June 30, 2025, from $4.43 million in the prior year.
• Research and Development expenses increased to $2.42 million from $1.60 million, primarily due to increased costs for drug product production and consulting for the Phase 2B study.
• General and Administrative expenses decreased to $1.74 million from $2.09 million, mainly due to staff reductions and lower professional service fees.
• Stock-based compensation decreased to $189,490 from $956,992.
• The company recognized a significant non-cash gain of $1.30 million from changes in the fair value of derivative liabilities for the six months ended June 30, 2025.
• Shareholders approved an increase in authorized common stock from 250 million to 1.25 billion shares and a potential reverse stock split.
• The company received a Nasdaq deficiency letter for not meeting the minimum bid price of $1.00, with a compliance period until September 15, 2025.
• Maturity dates for Series F and F-1 Preferred Stock were extended to December 31, 2025, and associated warrants (Series F and F-1) were extended to August 15, 2030.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, evidenced by the 'going concern' warning, negative working capital, and Nasdaq delisting threat. While R&D is progressing and net loss narrowed due to non-cash gains, the underlying operational cash burn increased, and significant dilution is ongoing. The extensions of debt maturity dates are temporary fixes, not long-term solutions, and highlight the company's precarious financial position.

Positives

• Significant reduction in net loss and loss per common share for the six months ended June 30, 2025, compared to the prior year.
• Successful initiation of a fully funded Phase 2b clinical trial for Isomyosamine in February 2024.
• Initiation of studies evaluating Isomyosamine for preserving lean muscle mass during GLP-1 treatment in January 2025.
• Positive results from the first stage of a general practice population study focusing on GLP-1 agonists, aiming to optimize patient recruitment for Isomyosamine.
• Formation of a philanthropic collaboration with the DADA2 Foundation for a Compassionate Use study of Isomyosamine.
• Non-cash gain of $1.30 million from changes in fair value of derivative liabilities for the six months ended June 30, 2025.
• Reduction in general and administrative expenses due to staff reductions and lower professional service fees.
• Extension of maturity dates for Series F and F-1 Preferred Stock to December 31, 2025, and associated warrants to August 15, 2030, providing more financial flexibility.

Negatives

• Substantial doubt about the company's ability to continue as a going concern due to sustained net losses and negative cash flows from operations.
• Working capital turned negative to $(397,585) as of June 30, 2025.
• Significant decrease in marketable securities from $8.35 million to $3.61 million, indicating cash utilization.
• Increased cash used in operating activities to $4.71 million for the six months ended June 30, 2025.
• Received a Nasdaq deficiency letter for not meeting the minimum bid price requirement of $1.00, risking delisting.
• Ongoing dilution risk from the conversion of preferred stock and exercise of warrants, as evidenced by the significant increase in common shares outstanding.
• Increased research and development expenses, indicating higher burn rate for clinical trials.
• Accumulated deficit increased to $133.85 million.

Risks

• Inability to obtain sufficient additional capital financing on acceptable terms, or at all, which would materially and adversely affect business, financial condition, and results of operations.
• Risk of delisting from The Nasdaq Capital Market if the minimum bid price requirement of $1.00 is not met by September 15, 2025, or within any extended compliance period.
• Significant dilution to existing stockholders from the issuance of additional equity.
• Uncertainty regarding the successful completion of clinical development, regulatory approval, and commercialization of product candidates (Isomyosamine and Supera-CBD).
• Dependence on third parties (CROs, CMOs) to conduct trials and manufacture product candidates.
• Challenges in maintaining regulatory approval if achieved.
• Impact of emerging competition and rapidly advancing technology in the industry.
• Inability to adequately protect or enforce intellectual property rights, including patents and trade secrets.
• Potential for adverse outcomes from ongoing litigation, such as the Raymond Akers Actions.
• Fluctuation and volatility in the market price of common stock.
• Challenges in achieving market acceptance for product candidates by providers, patients, patient advocacy groups, third-party payors, and the general medical community.
• Impact of pricing, insurance coverage, and reimbursement status of product candidates.
• Ability to retain and attract senior management and other key employees.

Future Outlook

The company anticipates significant increases in expenses as it advances the development of Isomyosamine and Supera-CBD, initiates new research, expands infrastructure, establishes agreements with CROs/CMOs, develops large-scale manufacturing, seeks marketing approvals, and builds sales/marketing/distribution capabilities. It will need substantial additional funding to support continuing operations and growth strategy. The Taxpayer Fairness and Growth Act of 2025, enacted post-period, is expected to favorably impact the effective tax rate starting fiscal 2026, though remeasurement of deferred tax balances may result in non-cash tax charges.

Management Comments

• We will not generate revenue from product sales unless and until we successfully complete clinical development, obtain regulatory approval for, and successfully commercialize our Isomyosamine and Supera-CBD product candidates.
• Any significant delay or failure to obtain regulatory approvals would materially adversely affect our product candidates development efforts and our business overall.
• We anticipate that our expenses will increase significantly as we advance the development of our Isomyosamine and Supera-CBD.
• It is difficult to project with absolute accuracy the duration or final cost of the development of Isomyosamine and Super-CBD or if revenue will be generated from the commercialization of these components.
• The process of achieving regulatory approval is very costly and time consuming.
• Management has substantial doubt about the Company’s ability to continue as a going concern.
• The Company’s ability to continue as a going concern for the next 12 months from the date of this Quarterly Report on Form 10-Q for the three and six months ended June 30, 2025, is dependent upon its ability to obtain additional capital financing.
• No assurance can be given that the Company will be successful in these efforts [to obtain additional funds].
• If the Company is unsuccessful in commercializing its products and raising capital, it will need to reduce activities, curtail or cease operations.

Industry Context

TNF Pharmaceuticals operates in the highly capital-intensive and regulated biotechnology and pharmaceutical industry, specifically focusing on novel therapeutic platforms like TNF-inhibitors and synthetic cannabinoids. The industry is characterized by lengthy and costly R&D cycles, high regulatory hurdles, and intense competition. The company's focus on age-related frailty, sarcopenia, and GLP-1 side effects positions it in growing areas of unmet medical need, particularly with the increasing use of GLP-1 agonists for weight loss. The use of AI and machine learning for patient identification aligns with broader industry trends towards precision medicine and data-driven drug development. However, the lack of product revenue and reliance on external financing are common for clinical-stage biotechs, but the "going concern" warning and Nasdaq deficiency highlight significant financial instability compared to more established players.

Comparison to Industry Standards

• R&D Focus: Similar to many early-stage biotech companies, TNF Pharmaceuticals is heavily invested in R&D with no current product revenue, which is standard for companies in the clinical trial phase.
• Cash Burn: The negative cash flow from operations ($4.71 million for six months) and the "going concern" warning are typical for clinical-stage biotechs but indicate a higher burn rate relative to current cash reserves compared to well-capitalized peers.
• Dilution: The significant increase in common shares outstanding (from 3.36 million to 29.38 million issued and outstanding, and 176.6 million outstanding as of Aug 18, 2025) and the approval for a massive increase in authorized shares (to 1.25 billion) and a potential reverse stock split are common strategies for struggling micro-cap biotechs to raise capital and maintain listing, but they represent substantial dilution compared to industry leaders who fund R&D through robust revenue streams or less dilutive financing.
• Nasdaq Compliance: The minimum bid price deficiency is a common challenge for smaller, pre-revenue biotechs, unlike larger pharmaceutical companies that typically maintain strong stock prices.
• Product Pipeline: Isomyosamine's focus on TNF-alpha and IL-6 inhibition for inflammatory diseases and sarcopenia places it in a competitive landscape with established TNF inhibitors (e.g., Humira, Enbrel) and emerging therapies. Its oral dosing and selective action could be differentiators if clinical success is achieved, but it is still in early clinical stages (Phase 2b) compared to late-stage or approved therapies.
• GLP-1 Side Effects: Targeting muscle loss associated with GLP-1 treatment is a novel and potentially high-growth area, aligning with the rapid expansion of the GLP-1 market (e.g., Novo Nordisk's Wegovy/Ozempic, Eli Lilly's Zepbound/Mounjaro). This niche could offer a competitive advantage if successful.
• AI/ML Adoption: The partnership with Renova Health to use AI/ML for patient identification is consistent with cutting-edge trends in drug development, aiming to accelerate trials, a practice increasingly adopted by innovative biopharma companies.

Management Changes

Corporate Governance

Legal Proceedings

• Raymond Akers Actions: Two lawsuits filed by Raymond F. Akers, Jr., Ph.D. against the company in New Jersey Superior Court, asserting common law whistleblower retaliation claims. The first action was dismissed, but the second, filed March 1, 2022, is in the discovery phase. The company believes this litigation will not have a material impact on its financial condition or results of operations.

Related Party Transactions

• SRQ Patent Holdings and SRQ Patent Holdings II: Royalty agreements (8% of net sales/milestone revenue/sublicense compensation) on products incorporating assigned intellectual property. These entities are affiliates of Mr. Jonnie Williams, Sr., a former significant stockholder. No revenue subject to these agreements for the reported periods.
• MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA): Amended and Restated Limited License Agreement (June 27, 2022, amended April 20, 2023) to share technical information and know-how for Supera-CBD and MIRA1a product candidates. The company holds patent rights to MIRA1a in 22 foreign countries and was granted a perpetual, non-exclusive, royalty-free license to use improvements to MIRA1a. MIRA received a limited, perpetual, worldwide, non-exclusive, royalty-free license to use Supera-CBD as a synthetic intermediate in MIRA1a manufacture.
• PharmaCyte Biotech, Inc.: An accredited investor in the Series G Private Placement (May 20, 2024). Joshua Silverman, interim CEO, President, and Director of PharmaCyte, serves as the company's Chairman of the Board.

Stakeholder Impact

• Shareholders: Face significant dilution risk from ongoing preferred stock conversions and warrant exercises. The approved increase in authorized common stock and potential reverse stock split further highlight this risk. The Nasdaq minimum bid price deficiency poses a delisting risk, which would severely impact liquidity and investor confidence.
• Employees: Staff reductions have occurred, impacting personnel costs. The company's "going concern" status creates uncertainty regarding job security and future compensation.
• Creditors/Preferred Stock Holders: The extensions of maturity dates for Series F and F-1 Preferred Stock provide temporary relief for the company but defer the repayment or conversion for these holders. The company's financial instability could impact the ultimate recoverability of their investments.
• Customers (potential): The progress in clinical trials for Isomyosamine and Supera-CBD offers potential future therapeutic options, particularly for conditions like age-related frailty, sarcopenia, and GLP-1 side effects.
• Suppliers/Partners: The company's financial health and "going concern" warning could affect its ability to secure favorable terms or maintain relationships with contract research organizations (CROs) and contract manufacturing organizations (CMOs).

Next Steps

• Regain compliance with Nasdaq's minimum bid price requirement by September 15, 2025.
• Obtain additional capital financing through future offerings of preferred or common stock, private equity, or debt financings.
• Continue advancing the development of Isomyosamine and Supera-CBD product candidates.
• Initiate and continue research and preclinical and clinical development of potential new product candidates.
• Maintain, expand, and protect intellectual property.
• Expand infrastructure and facilities.
• Establish agreements with CROs and CMOs.
• Develop large-scale manufacturing processes.
• Seek marketing approvals for product candidates.
• Establish sales, marketing, and distribution infrastructure.
• Evaluate the impact of the Taxpayer Fairness and Growth Act of 2025 on financial statements and recognize required adjustments.
• Continue discovery phase for the Second Raymond Akers Action legal proceeding.

Key Dates

Recommendation

The company is in a highly precarious financial position, explicitly stating "substantial doubt about its ability to continue as a going concern." This fundamental risk is compounded by negative working capital, increasing operational cash burn, and a Nasdaq minimum bid price deficiency that threatens delisting. While the net loss narrowed, this was largely due to non-cash gains on derivatives, masking an underlying increase in cash used for operations. The continuous need for capital raises, coupled with massive authorized share increases and planned reverse stock splits, indicates severe and ongoing dilution for common shareholders. Despite some clinical progress, the financial instability and high risk of delisting make this an extremely speculative investment with significant downside potential.

Keywords

TNF Pharmaceuticals, TNFA, Biotechnology, Pharmaceuticals, Clinical Stage, Isomyosamine, Supera-CBD, Autoimmune Disease, Frailty, Sarcopenia, GLP-1, Inflammation, Drug Development, Nasdaq Compliance, SEC Filing, 10-Q, Preferred Stock, Warrants, Dilution, Going Concern, Clinical Trials, DADA2 Foundation